BridgeMD
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms
EU CTIS ID: 2024-516156-18-00
What this study is testing
To develop models based on tumor measurements derived from combined 18FDG and 64Cu-DOTATATE PET/CT scans to predict progression-free survival for patients with neuroendocrine neoplasms.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age above or of 18 years
- Histopathologically verified gastro-pancreatic neuroendocrine neoplasm (GEP-NEN: GEP NET G1-G3 or GEP-NEC) or unknown primary tumor with NEN-positive metastases suggesting GEP origin on pathology examination.
- Must be able to read and understand the patient information in Danish and to give informed consent.
- WHO Performance status 0-2.
You likely can't join if
- Pregnancy
- Localized neuroendocrine neoplasms of the appendix, the rectum measuring < 1 cm, and ECL-omas of the stomach
- History of allergic reaction attributable to compounds of similar chemical or biologic composition to 18FDG or 64Cu-DOTATATE
- Breast-feeding
- Weights more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)
- Uncontrolled diabetes
See the full eligibility criteria
- Age above or of 18 years
- Histopathologically verified gastro-pancreatic neuroendocrine neoplasm (GEP-NEN: GEP NET G1-G3 or GEP-NEC) or unknown primary tumor with NEN-positive metastases suggesting GEP origin on pathology examination.
- Must be able to read and understand the patient information in Danish and to give informed consent.
- WHO Performance status 0-2.
- Pregnancy
- Localized neuroendocrine neoplasms of the appendix, the rectum measuring < 1 cm, and ECL-omas of the stomach
- History of allergic reaction attributable to compounds of similar chemical or biologic composition to 18FDG or 64Cu-DOTATATE
- Breast-feeding
- Weights more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)
- Uncontrolled diabetes
- Uncontrolled infection
- Exacerbation in autoimmune diseases
- Other active cancer disease
- Conditions or diseases (e.g. uncontrolled Parkinson’s disease) making the patient unable to lie still in the scanner
- Severe claustrophobia
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.